Wave Life Sciences (WVE) Q1 2026 earnings summary

Executive summary

• Advanced lead programs WVE-007 (obesity), WVE-006 (AATD), and WVE-008 (PNPLA3 liver disease), with WVE-008 progressing toward clinic entry in 2026.

• WVE-007 demonstrated significant, durable visceral fat loss and muscle preservation in phase I, supporting infrequent dosing; phase II-A to initiate in higher BMI patients in 2Q 2026.

• WVE-006 showed restoration of dynamic AAT response and reduction of harmful Z-AAT, with regulatory feedback on accelerated approval expected mid-2026 and new data to be presented at major conferences.

• Pipeline expansion includes bifunctional modalities, new hepatic/extrahepatic candidates, and ongoing collaborations, notably with GSK.

• Company is transitioning its parent domicile from Singapore to Delaware, subject to approvals.

Financial highlights

• Q1 2026 revenue was $38.2M, up from $9.2M year-over-year, mainly due to GSK collaboration and regaining full rights to WVE-006.

• R&D expenses rose to $47.4M from $40.6M year-over-year; G&A expenses increased to $22.1M from $18.4M.

• Net loss narrowed to $26.1M from $46.9M year-over-year; net loss per share improved to $(0.13) from $(0.29).

• Cash and equivalents at quarter-end were $544.6M, expected to fund operations into Q3 2028.

• Weighted-average shares outstanding: 200.2 million for Q1 2026.

Outlook and guidance

• Cash position expected to fund operations into Q3 2028, excluding potential milestone payments.

• Phase II-A trial of WVE-007 in higher BMI patients (with/without diabetes) to initiate in 2Q 2026; combination and maintenance studies planned for 2026.

• Additional WVE-007 phase I and II-A data, including higher dose cohorts, expected in 2026.

• WVE-006 regulatory feedback on accelerated approval pathway anticipated mid-2026; expanded data to be presented at ATS conference.

• WVE-008 CTA submission on track for 2026.